Cargando…
FAT10 is associated with the malignancy and drug resistance of non-small-cell lung cancer
Lung cancer has become one of the leading causes of cancer mortality worldwide, and non-small-cell lung cancer (NSCLC) accounts for ~85% of all lung cancer cases. Currently, platinum-based chemotherapy drugs, including cisplatin and carboplatin, are the most effective treatment for NSCLC. However, t...
Autores principales: | Xue, Feng, Zhu, Lin, Meng, Qing-wei, Wang, Liyan, Chen, Xue-song, Zhao, Yan-bin, Xing, Ying, Wang, Xiao-yun, Cai, Li |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4959415/ https://www.ncbi.nlm.nih.gov/pubmed/27499634 http://dx.doi.org/10.2147/OTT.S98410 |
Ejemplares similares
-
Notch signaling and non-small cell lung cancer
por: Zou, Bin, et al.
Publicado: (2018) -
TRIM44 promotes proliferation and metastasis in non-small cell lung cancer via mTOR signaling pathway
por: Xing, Ying, et al.
Publicado: (2016) -
Prevalence of tuberculosis drug resistance in 10 provinces of China
por: He, Guang Xue, et al.
Publicado: (2008) -
Establishment and Characterization of a Topotecan Resistant Non-small Cell Lung Cancer NCI-H460/TPT10 Cell Line
por: Lei, Zi-Ning, et al.
Publicado: (2020) -
PHLPP2 as a novel metastatic and prognostic biomarker in non‐small cell lung cancer patients
por: Wang, Hongmei, et al.
Publicado: (2019)